In the bivariate analysis, factors statistically significant associated with the development of DKF were: glomerular sclerosis, fibrous crescents, interstitial cell infiltration and tubular atrophy; having membranous component resulted as a "protector" factor for the development of DKF. The Cox regression model included all the factors with a p-value less than 0.25 in the bivariate analysis; independent factors associated with increased HR of DKF were glomerular sclerosis and fibrous crescents; however, hyaline thrombi and presence of membranous nephritis were associated with a decreased HR of DKF. (Table 1) Background: Osteoarthritis (OA) is the most prevalent joint disease and the leading cause of disability from 60 years onwards. In fact, 14,8% of the Spanish population has OA. Objectives: This study aimed to determine if there is a differential profile and greater comorbidity in women affected by symptomatic knee OA compared to a control group without OA. Methods: The EMARTRO study was designed as an observational, multicenter, transversal study to compare probability of suffering a comorbidities based on presence of symptomatic knee OA visited by GPs. Sociodemographic, anthropometric, clinical parameters and clinical variables of interest were recorded. The probability of suffering comorbidities in each study group was estimated using the Odds Ratio estimation with conditioned logistic regression models. The HAD scale, the Goldberg health questionnaire were administered to patients and the concomitant medication was also registered. The comparison between groups was done using t-Student, Chi-square and Mann-Whitney. Results: A total of 897 women were included with a mean (SD) age of 67.4 (6.8) years. Osteoarthritic women were obese and had a higher BMI compared with control group, 31.2 (5.5) vs 27.5 (4.3) (p<0.0001), respectively. Regarding blood pressure, no differences were found in the systolic BP (p=0.0646) but in the diastolic, women with OA also had higher values, 77.9 (9.1) vs 75.8 (8.9) mmHg (p=0.0005). In general terms, the presence of OA doubled the probability of having concomitant conditions with respect to controls [OR=2,220 (95% CI: 1,449-3,400) p=0,0002]. Likewise, women with syntomatic knee OA were more likely to have hypertension [OR=1.697 (95% CI 1.299-2.217), p=0.0001], venous peripheral vascular disease [OR=2.148 (95% CI 1.547-2.984), p<0.0001] and gastroesophageal reflux (OR=1.890 (95% CI 1.297-2.754), p=0.0009). Regarding the mental health of the patients, according to the Goldberg scale, 41% of the patients with OA elicited psychopathology vs 17.8% in controls, p<0.0001. As for the HAD scale, there were more cases of anxiety (p<0.0001) and depression in the OA women (p<0.0001). The greater burden of physical and mental comorbidity in the OA patients was accompanied by a higher consumption of concomitant medications (p<0.0001).
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Conclusions:
The results of the present study indicate that in patients with knee OA, being female is a risk factor for the development of concomitant pathologies. Also, the increased likelihood of suffering from hypertension, venous peripheral vascular disease and gastroesophageal reflux should determine chronic medications for the treatment of osteoarthritis. Background: Young adults with acute myocardial infarction are a critical group to examine for the purpose of risk factors stratification and modification [1] . In the setting of underlying systemic autoimmune diseases, premature cardiovascular disease deserves even more attention in these conditions, such as antiphospholipid syndrome (APS), the most common acquired thrombophilia. Objectives: In this study we aimed to assess the clinical utility of the adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) [2] for the risk stratification of acute myocardial infarction in a cohort of young APS patients with thrombotic events. Methods: The analysis included 83 consecutive APS patients (≤50 years old) who presented with arterial or venous thromboembolic events. Data on cardiovascular risk factors and antiphospholipid antibodies (aPL) positivity were retrospectively collected. The aGAPSS was calculated for each patient by adding the points corresponding to the risk factors, based on a linear transformation derived from the β regression coefficient as follows: 3 for hyperlipidaemia, 1 for arterial hypertension, 5 for aCL IgG/IgM, 4 for anti-b2 glycoprotein I IgG/IgM and 4 for LA. Results: Demographic, clinical and laboratory characteristics of the cohort are summarized in Table 1 Background: Previous studies reported active tuberculosis infections can occur during biologic treatment in patients with negative baseline LTBI screening. Current recommendations suggesting the annual testing for latent tuberculosis infections are mainly issued for patients with rheumatoid arthritis (RA) receiving anti-TNF inhibitors and there are lacking evidence for patients receiving non-TNF biologic agents and for patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA). Objectives: This study was performed to investigate the conversion rate of initially negative tuberculosis screening test results during biologic treatment and the usefulness of repeated screening test for detecting unexpected tuberculosis infection in patients with RA, AS, and PsA. Methods: A total of 95 patients (43 with RA, 50 with AS, and 2 with PsA) who had negative baseline interferon γ releasing assay (IGRA) results, which were assessed using QuatiFERON-TB Gold in tube (QTF-GIT), prior to initiation of biologic treatment were enrolled in this study. All patients received biologic agents for the treatment of their diseases and rescreening with QTF-GIT were performed in all patients after median 12 months from baseline test. Clinical characteristics were compared between converters and non-converters and incidence of active tuberculosis infection was evaluated. Results: Patients were treated with different biologics (23 with etanercept, 50 with adalimumab, 5 with infliximab, 4 with golimumab, 1 with certolizumab pegol, 3 with abatacept, and 9 with tocilizumab). Positive conversions of initially negative IGRA were found in 13 (6 patients with etanercept, 4 patients with adalimumab, 2 patients with tocillizumab and 1 patient with abatacept) of 95 patents (13.7%) after initiation of biologic treatment. Age over 50 years and diagnosis of RA were more common in converters. Multivariate analysis showed that age over 50 was an independent risk factor for IGRA conversion with OR 4.36 (95% CI 1.10 -17.34, p=0.036). During biologic treatments, active tuberculous infections were found in 3 of 13 converters (23.1%) Conclusions: Although initial screening test showed negative results, the serial follow-up of tuberculosis screening test should be considered during biologic treatment in patients with rheumatic diseases to prevent unexpected tuberculosis infection. 
